Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

Trends in in vivo models targeting respiratory diseases

3 May 2017
Journal articles

Magazines publication Newspaper and journal books: background and catalog design; article magazine press; newspaper media book knowledge; document advertising datum textbook


Summary

For the past 50 years, the principle of the 3Rs (replacement, reduction and refinement) has effectively reduced the use of animals in preclinical studies.

Though some complex alternatives are available to support efficacy and safety assessment, in vivo studies are still necessary to translate the science from bench to man.

Continued enhancements of validated in vivo models targeting respiratory diseases are incorporating more clinically relevant biomarker and functional endpoints to maximize the outcomes from each animal.

This White Paper Includes:

  • Understand how the 3Rs are improving in vivo model outcomes
  • Learn how market trends are impacting Big Pharma
  • Discover areas of new in vivo developments
  • Explore how including multiplex, clinically relevant endpoints improve effectiveness of studies

Click here to view the White Paper

Click here for more information on Envigo

Top content

  • Novel liquid biopsy test enhances early cancer detection with high accuracy
  • Major M&A deals impacting bioanalysis in 2025
Previous article Next article

  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone